This page shows the latest Relvar news and features for those working in and with pharma, biotech and healthcare.
GlaxoSmithKline's struggling respiratory division has had more bad news, with new product Breo/Relvar failing to improve survival in a trial involving patients with chronic obstructive pulmonary disease (COPD).
Relvar (fluticasone furoate/vilanterol) which became the first once-daily product of its type, have injected more competition into the marketplace.
But respiratory drug given the thumbs up for adults only
The product is sold as Relvar in some markets and is a follow-up to GSK's blockbuster Seretide/Advair product and combines LABA vilanterol with the inhaled corticosteroid (ICS) fluticasone
up Relvar/Breo (fluticasone furoate and vilanterol) - to get off to a flying start in the increasingly competitive respiratory sector.
combination Anoro (umeclidinium and vilanterol) and Advair follow-up Relvar/Breo (fluticasone furoate and vilanterol) - to get the division back on track.
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.